SELLAS Life Sciences Group, Inc

(NASDAQ:SLS)

Latest On SELLAS Life Sciences Group, Inc (SLS):

Date/Time Type Description Signal Details
2023-05-12 00:38 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.47 misses by $0.18N/A
2023-03-16 23:15 ESTNewsSELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-lineN/A
2023-02-24 22:17 ESTNewsSellas Life Sciences dips after pricing $20M securities offeringN/A
2023-02-23 19:33 ESTNewsSELLAS stock slides -32% after launching stock and warrants offeringN/A
2022-11-14 15:03 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.34 beats by $0.05N/A
2022-11-14 15:03 ESTNewsSELLAS falls 39% after delaying key milestone for cancer drugN/A
2022-11-10 23:10 ESTNewsSellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trialN/A
2022-08-12 07:49 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.41 misses by $0.02N/A
2022-08-10 05:35 ESTNewsSELLAS Life Sciences rises 9% after cancer drug shows promising result in animal studyN/A
2022-06-27 15:37 ESTNewsSellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapyN/A
2022-06-17 01:19 ESTNewsSELLAS Life Sciences Group (SLS) Investor Presentation - SlideshowN/A
2022-06-09 00:39 ESTNewsSellas' GPS, Opdivo combo shows promise in early stage study in type of lung cancerN/A
2022-05-26 17:45 ESTNewsSellas announces topline data for lead asset in Ovarian cancerN/A
2022-05-13 00:44 ESTNewsSELLAS Life Sciences GAAP EPS of -$1.05, revenue of $1MN/A
2022-04-06 21:12 ESTNewsSellas Life Sciences gets China regulator nod to start trial of immunotherapy 3D189N/A
2022-04-01 12:06 ESTNewsSELLAS Life Sciences plunged 24% on $25M stock offeringN/A
2022-03-31 17:59 ESTNewsSellas Life Sciences stock slumps on securities offeringN/A
2022-03-31 17:59 ESTNewsSellas Life Sciences licenses CDK9 inhibitor from China's GenFleet TherapeuticsN/A
2022-02-02 08:19 ESTNewsSellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancerN/A
2022-01-27 20:28 ESTNewsSELLAS Life Sciences' IND application for galinpepimut-S accepted in ChinaN/A
2021-11-24 05:30 ESTNewsSellas Life announces final court approval of settlement of derivative litigationN/A
2021-11-24 05:30 ESTNewsWarning: SLS is at high risk of performing badlyN/A
2021-11-13 03:57 ESTNewsSELLAS Life Sciences EPS misses by $0.09N/A
2021-08-13 00:18 ESTNewsSELLAS Life Sciences EPS beats by $0.11N/A
2021-07-22 01:01 ESTNewsSellas Life Sciences nabs new U.S. patent for galinpepimut-s combo in WT1-expressing cancersN/A
2021-07-22 00:57 ESTNewsSELLAS Life Sciences updates on at-the-market offeringN/A
2021-07-22 00:31 ESTNewsSELLAS Life Sciences shares rise on data from early-stage galinpepimut-S studyN/A
2021-07-22 00:23 ESTNewsSELLAS ovarian cancer candidate shows promise in early-stage trialN/A
2021-07-21 23:56 ESTNewsSELLAS rated new overweight at Cantor noting the potential of blood cancer therapyN/A
2021-03-24 06:05 ESTNewsSELLAS Life Sciences EPS misses by $0.28N/A
2021-02-23 02:51 ESTNewsSellas: Late-Stage Biotech Approaches 2023 Approval With Solid FundingN/A
2021-02-04 01:42 ESTNewsSELLAS Life Sciences jumps 43% after Reddit mentionsN/A
2020-12-23 04:40 ESTAnalyst RatingThe Analyst Target Price has increased from $8 to $10.Buy
2020-12-21 14:55 ESTNewsSellas' galinpepimut-S combo shows promising action in early-stage solid tumor studiesN/A
2020-12-17 23:52 ESTNewsSellas Life Sciences strengthens balance sheet with addition of $30.5MN/A
2020-12-14 07:39 ESTNewsSellas Life Sciences prices $16.2M direct offeringN/A
2020-12-11 11:44 ESTNewsNelipepimut-S data from breast cancer study fails to lift SELLAS Life SciencesN/A
2020-12-08 12:06 ESTNewsSELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater ChinaN/A
2020-11-26 21:35 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 21:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:25 ESTEarnings EstimateAn EPS average of -$0.35 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-14 11:21 ESTNewsSELLAS Life Sciences EPS misses by $0.26N/A
2020-11-08 00:54 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:09 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 14:03 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:16 ESTFinancialsCompany financials have been released.Neutral
2020-09-10 05:25 ESTNewsSELLAS Life gets green signal to initiate late-stage blood cancer study with GPS in FranceN/A
2020-09-01 21:38 ESTFinancialsCompany financials have been released.Neutral
2020-08-20 13:43 ESTAnalyst RatingThe Analyst Target Price has decreased from $8.5 to $8.Neutral
2020-08-17 01:43 ESTFinancialsCompany financials have been released.Neutral

About SELLAS Life Sciences Group, Inc (SLS):

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

SLS Quotes by TradingView

See Advanced Chart

General

  • Name SELLAS Life Sciences Group, Inc
  • Symbol SLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 5
  • Last Split Factor1:50
  • Last Split Date2019-11-08
  • Fiscal Year EndDecember
  • IPO Date2017-12-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.sellaslifesciences.com
View More

Valuation

  • Trailing PE 0.62
  • Price/Book (Most Recent Quarter) 17.57
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.30
  • Return on Assets -55%
  • Return on Equity -220%
  • Earnings Per Share -$1.35
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 149.61 million
  • PE Ratio -2.01
  • Analyst Target Price $10
  • Book Value Per Share $0.84
View More

Share Statistics

  • Shares Outstanding 14.19 million
  • Shares Float 9.22 million
  • % Held by Insiders 198%
  • % Held by Institutions 14.24%
  • Shares Short 805001
  • Shares Short Prior Month 960419
  • Short Ratio 0.22
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.87
  • 52 Week High $12.18
  • 52 Week Low $1.46
  • 50 Day Moving Average 8.9
  • 200 Day Moving Average 5.21
View More

Dividends

  • Dividend Date 2019-11-08
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

SELLAS Life Sciences Group, Inc (SLS) Dividend Calendar:

SLS's last dividend payment was made to shareholders on November 8, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

SELLAS Life Sciences Group, Inc (SLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.53-$0.27-96.3%
2020-06-302020-08-13$N/A-$0.66-$0.64-3.13%
2020-03-312020-05-14$N/A-$0.66
2019-12-312020-03-13$N/A-$1.54-$0.72-113.89%
2019-09-302019-11-14$N/A-$2.68-$1.00-168%
2019-06-302019-08-14$N/A-$6.50-$9.0027.78%
2019-03-312019-05-15$N/A-$11.00-$11.504.35%
2018-12-312019-03-22$N/A-$20.00-$11.75-70.21%
2018-09-302018-11-14$N/A-$26.50-$20.25-30.86%
2018-06-302018-08-14$N/A-$63.00-$51.50-22.33%
2018-03-312018-05-15$N/A-$83.50-$46.50-79.57%
2017-09-302017-11-09$N/A-$135.00-$4.50-2900%
2017-06-302017-08-14$N/A-$6.60-$5.40-22.22%
2017-03-312017-05-10$N/A-$13.50-$6.60-104.55%
2016-12-312017-03-15$N/A-$14.70-$15.605.77%
2016-09-302016-11-09$N/A-$18.00-$27.0033.33%
2016-06-302016-08-09$N/A$18.00-$37.50148%
2016-03-312016-05-10$N/A-$54.00-$38.40-40.63%
2015-12-312016-03-10$6.13 million-$72.00-$32.00-125%
2015-09-302015-11-09$-9514000-$2.20-$1.37-60.58%
2015-06-302015-08-06$3.38 million-$2.00-$1.84-8.7%
2015-03-312015-05-07$2.75 million-$1.60-$1.737.51%
2014-12-312015-03-05$9.48 million-$1.20-$2.1042.86%
2014-09-302014-11-03$-2884000-$0.05-$0.1154.55%
2014-06-302014-08-11$4.5 million-$5,100.00-$2,700.00-88.89%
2014-03-312014-05-06$-165000-$600.00-$2,062.5070.91%
2013-12-312014-03-17$1.32 million-$13,800.00-$2,766.67-398.79%
2013-09-302013-11-06$1.17 million-$3,300.00-$3,300.000%
2013-06-302013-08-08$N/A-$3,300.00-$3,112.50-6.02%
2013-03-312013-05-09$N/A-$3,300.00-$2,228.57-48.08%
2012-12-312013-03-12$N/A-$1,200.00-$3,042.8660.56%
2012-09-302012-11-13$N/A-$2,700.00-$2,550.00-5.88%
2012-06-302012-08-14$N/A-$210.00-$4,800.0095.63%
2012-03-312012-05-14$N/A-$15,600.00-$3,000.00-420%
2011-12-312012-03-28$1,200.00-$4,500.00126.67%
2011-09-302011-11-14$N/A-$3,900.00-$4,800.0018.75%
2011-06-302011-08-15$N/A-$1,200.00-$2,100.0042.86%
2011-03-312011-05-15-$5,672.40
2010-09-302010-11-15-$6,900.00-$7,050.002.13%
2010-06-302010-08-11-$3,600.00-$7,200.0050%
2010-03-312010-05-17-$7,200.00-$8,100.0011.11%
2009-12-312010-03-31-$11,400.00-$7,500.00-52%
2009-09-302009-11-16-$5,846.95
2009-06-302009-08-14-$11,100.00-$9,000.00-23.33%
2009-03-312009-05-15-$9,000.00-$8,700.00-3.45%
2008-12-312009-03-18-$8,700.00$2,400.00-462.5%
2008-09-302008-11-14-$7,500.00-$9,600.0021.88%
2008-06-302008-08-14-$10,200.00-$6,600.00-54.55%
2008-03-312008-04-15-$11,700.00-$6,000.00-95%

SELLAS Life Sciences Group, Inc (SLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

SELLAS Life Sciences Group, Inc (SLS) Chart:

SELLAS Life Sciences Group, Inc (SLS) News:

Below you will find a list of latest news for SELLAS Life Sciences Group, Inc (SLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

SELLAS Life Sciences Group, Inc (SLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-05-160.50.7CALL0 22947.04TRUE00
2025-05-1610.6CALL54 298330.24TRUE-0.15-0.2
2025-05-161.50.15CALL118 2943149.73TRUE-0.1-0.4
2025-05-1620.01CALL75 1209133.65FALSE-0.04-0.8
2025-05-162.50.07CALL0 162320.32FALSE00
2025-05-1630.05CALL0 118395.33FALSE00
2025-05-1640.04CALL0 46956.74FALSE00
2025-05-1650CALL0 0771.9FALSE00
2025-05-160.50.05PUT0 100635.28FALSE00
2025-05-1610.04PUT0 301182.73FALSE00
2025-05-161.50.09PUT145 162151.06FALSE0.040.8
2025-05-1620.05PUT0 31501.89TRUE00
2025-05-162.50.8PUT0 1751.92TRUE00
2025-05-1630PUT0 0284.38TRUE00
2025-05-1640PUT0 0530.57TRUE00
2025-05-1650PUT0 0709.75TRUE00
2025-06-200.51.35CALL0 1436.99TRUE00
2025-06-2010.85CALL0 692170.14TRUE00
2025-06-201.50.25CALL152 2517105.75TRUE-0.13-0.34
2025-06-2020.14CALL412 2990131.71FALSE0.010.08
2025-06-202.50.1CALL6 950154.42FALSE-0.02-0.17
2025-06-2030.05CALL467 2147150.6FALSE00
2025-06-2040.05CALL0 27377.4FALSE00
2025-06-2050.05CALL0 415192.75FALSE00
2025-06-200.50.1PUT4 50379.62FALSE0.10
2025-06-2010.05PUT0 35161.28FALSE00
2025-06-201.50.23PUT0 106114.21FALSE00
2025-06-2020.5PUT0 2057.22TRUE00
2025-06-202.50PUT0 0165.72TRUE00
2025-06-2030PUT0 0183.1TRUE00
2025-06-2040PUT0 0261.1TRUE00
2025-06-2050PUT0 0310.56TRUE00
2025-07-180.51.19CALL0 338521.91TRUE00
2025-07-1810.65CALL92 2553129.62TRUE-0.08-0.11
2025-07-181.50.35CALL68 6811119.59TRUE-0.05-0.13
2025-07-1820.2CALL307 5126123.85FALSE-0.01-0.05
2025-07-182.50.25CALL2 769179.08FALSE0.10.67
2025-07-1830.1CALL5 97142.76FALSE0.10
2025-07-1840.05CALL0 504222.82FALSE00
2025-07-1850.05CALL51 2007170.45FALSE00
2025-07-180.50.25PUT0 1472.78FALSE00
2025-07-1810.2PUT0 7201.35FALSE00
2025-07-181.50.3PUT0 20128FALSE00
2025-07-1821.15PUT0 2132.84TRUE00
2025-07-182.50PUT0 0198.47TRUE00
2025-07-1830PUT0 0155.78TRUE00
2025-07-1840PUT0 0236.59TRUE00
2025-07-1853.9PUT0 10243.69TRUE00
2025-10-170.51.25CALL0 54257.13TRUE00
2025-10-1710.9CALL40 19181.36TRUE0.90
2025-10-171.50.4CALL0 62143.85TRUE00
2025-10-1720.35CALL18 7182116.6FALSE-0.1-0.22
2025-10-172.50.3CALL18 261128.8FALSE-0.05-0.14
2025-10-1730.49CALL52 259192.69FALSE0.140.4
2025-10-170.50PUT0 0313.09FALSE00
2025-10-1710PUT0 0192.18FALSE00
2025-10-171.50PUT0 0119.2FALSE00
2025-10-1720PUT0 0132.99TRUE00
2025-10-172.50PUT0 0128.13TRUE00
2025-10-1730PUT0 0134.48TRUE00
2026-01-160.51.25CALL83 1794203.91TRUE-0.04-0.03
2026-01-1611CALL8 7115176.1TRUE10
2026-01-161.50.6CALL4 4853113.68TRUE-0.1-0.14
2026-01-1620.45CALL59 29760111.76FALSE-0.1-0.18
2026-01-162.50.5CALL0 1037171.46FALSE00
2026-01-1630.3CALL10 3428116.11FALSE-0.06-0.17
2026-01-1640.25CALL1020 9091126.02FALSE-0.05-0.17
2026-01-160.50.1PUT0 12218.73FALSE00
2026-01-1610.3PUT0 107215.41FALSE00
2026-01-161.50.95PUT0 1160.38FALSE00
2026-01-1620.95PUT0 4103.53TRUE00
2026-01-162.51.3PUT0 14134.49TRUE00
2026-01-1631.7PUT0 33155.16TRUE00
2026-01-1642.79PUT0 2122.89TRUE00
2027-01-150.51.18CALL66 224297.56TRUE-0.08-0.06
2027-01-1510.94CALL34 1120796.73TRUE0.040.04
2027-01-151.50.77CALL2 259095.56TRUE-0.13-0.14
2027-01-1520.65CALL0 87285.35FALSE00
2027-01-152.50.68CALL0 174114.4FALSE00
2027-01-1530.63CALL13 198113.85FALSE-0.02-0.03
2027-01-1540.5CALL30 218110.25FALSE-0.08-0.14
2027-01-150.50.17PUT0 5143.66FALSE00
2027-01-1510.7PUT0 10130.73FALSE00
2027-01-151.50.62PUT0 799.4FALSE00
2027-01-1521.05PUT10 177104.73TRUE1.050
2027-01-152.50PUT0 0112.17TRUE00
2027-01-1532PUT0 20110.1TRUE00
2027-01-1543.03PUT0 2126.97TRUE00

Latest SLS Trades:

Date Shares Price
Jun 13, 2022 7:06 PM EST5$2.29
Jun 13, 2022 7:12 PM EST100$2.265
Jun 13, 2022 7:30 PM EST100$2.265
Jun 13, 2022 7:39 PM EST2$2.28
Jun 13, 2022 7:40 PM EST100$2.27

SELLAS Life Sciences Group, Inc (SLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm
2018-07-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000018022947/0000000000-18-022947-index.htm
2019-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000019009082/0000000000-19-009082-index.htm
2019-10-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000019014150/0000000000-19-014150-index.htm
2020-06-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000020005052/0000000000-20-005052-index.htm
2020-08-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000020007844/0000000000-20-007844-index.htm
2018-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924318025346/0000899243-18-025346-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008194/0000899243-19-008194-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008198/0000899243-19-008198-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008199/0000899243-19-008199-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008201/0000899243-19-008201-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008202/0000899243-19-008202-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008204/0000899243-19-008204-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008205/0000899243-19-008205-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008206/0000899243-19-008206-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008207/0000899243-19-008207-index.htm
2018-07-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000090266418002884/0000902664-18-002884-index.htm
2019-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000090266419000274/0000902664-19-000274-index.htm
2018-07-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000101359418000463/0001013594-18-000463-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000101359420000125/0001013594-20-000125-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000103738919000077/0001037389-19-000077-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000103738920000128/0001037389-20-000128-index.htm
2019-10-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1390478/000110465919057371/0001104659-19-057371-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/0001104659-19-057956-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/0001104659-19-060564-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920002021/0001104659-20-002021-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920002807/0001104659-20-002807-index.htm
2020-01-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1390478/000110465920002811/0001104659-20-002811-index.htm
2020-01-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920004932/0001104659-20-004932-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920033156/0001104659-20-033156-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034285/0001104659-20-034285-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034288/0001104659-20-034288-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034289/0001104659-20-034289-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034290/0001104659-20-034290-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920049860/0001104659-20-049860-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1390478/000110465920050563/0001104659-20-050563-index.htm
2020-05-29S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000110465920067795/0001104659-20-067795-index.htm
2020-06-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1390478/000110465920069457/0001104659-20-069457-index.htm
2020-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000110465920071368/0001104659-20-071368-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920072436/0001104659-20-072436-index.htm
2020-06-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000110465920072467/0001104659-20-072467-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/0001104659-20-089747-index.htm
2020-08-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000110465920095588/0001104659-20-095588-index.htm
2020-08-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000110465920097531/0001104659-20-097531-index.htm
2019-04-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419018433/0001144204-19-018433-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419028003/0001144204-19-028003-index.htm
2019-05-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419028175/0001144204-19-028175-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419029019/0001144204-19-029019-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419029269/0001144204-19-029269-index.htm
2019-06-06S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419030128/0001144204-19-030128-index.htm
2019-06-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419030762/0001144204-19-030762-index.htm
2019-06-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419030766/0001144204-19-030766-index.htm
2019-06-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419030768/0001144204-19-030768-index.htm
2019-06-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1390478/000114420419031239/0001144204-19-031239-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/0001144204-19-031351-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419033573/0001144204-19-033573-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/0001144204-19-034049-index.htm
2019-07-26PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419036263/0001144204-19-036263-index.htm
2019-08-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419037528/0001144204-19-037528-index.htm
2019-09-20S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419045463/0001144204-19-045463-index.htm
2019-10-04S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419047400/0001144204-19-047400-index.htm
2019-10-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419047401/0001144204-19-047401-index.htm
2018-07-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518217974/0001193125-18-217974-index.htm
2018-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/0001193125-18-220669-index.htm
2018-07-19S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000119312518221592/0001193125-18-221592-index.htm
2018-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518223727/0001193125-18-223727-index.htm
2018-07-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1390478/000119312518223824/0001193125-18-223824-index.htm
2018-07-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000119312518225863/0001193125-18-225863-index.htm
2018-07-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518227864/0001193125-18-227864-index.htm
2018-07-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518227881/0001193125-18-227881-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518239831/0001193125-18-239831-index.htm
2018-10-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1390478/000119312518296150/0001193125-18-296150-index.htm
2018-10-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518301115/0001193125-18-301115-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312519003893/0001193125-19-003893-index.htm
2019-06-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000119312519180113/0001193125-19-180113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000119312520038502/0001193125-20-038502-index.htm
2018-12-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000120919118063530/0001209191-18-063530-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm
2019-10-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000130049119000007/0001300491-19-000007-index.htm
2018-07-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713118003284/0001387131-18-003284-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713119001111/0001387131-19-001111-index.htm
2019-06-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713119004559/0001387131-19-004559-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713120001689/0001387131-20-001689-index.htm
2020-08-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713120007841/0001387131-20-007841-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047818000022/0001390478-18-000022-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000025/0001390478-18-000025-index.htm
2018-10-058-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000027/0001390478-18-000027-index.htm
2018-10-248-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000030/0001390478-18-000030-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/0001390478-18-000032-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047818000035/0001390478-18-000035-index.htm
2018-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000037/0001390478-18-000037-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000039/0001390478-18-000039-index.htm
2018-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000043/0001390478-18-000043-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000007/0001390478-19-000007-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/0001390478-19-000011-index.htm
2019-03-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000017/0001390478-19-000017-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000019/0001390478-19-000019-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000023/0001390478-19-000023-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000028/0001390478-19-000028-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000030/0001390478-19-000030-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000033/0001390478-19-000033-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000035/0001390478-19-000035-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000037/0001390478-19-000037-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000044/0001390478-19-000044-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000045/0001390478-19-000045-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000048/0001390478-19-000048-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000056/0001390478-19-000056-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000057/0001390478-19-000057-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000061/0001390478-19-000061-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/0001390478-20-000007-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000009/0001390478-20-000009-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000014/0001390478-20-000014-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000015/0001390478-20-000015-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000026/0001390478-20-000026-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000029/0001390478-20-000029-index.htm
2020-08-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000030/0001390478-20-000030-index.htm
2020-09-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000149315220018054/0001493152-20-018054-index.htm
2019-01-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000153561019000006/0001535610-19-000006-index.htm
2018-07-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999518001908/9999999995-18-001908-index.htm
2019-06-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999519001347/9999999995-19-001347-index.htm
2019-10-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999519002300/9999999995-19-002300-index.htm
2020-06-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm
2020-08-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520002237/9999999995-20-002237-index.htm

SELLAS Life Sciences Group, Inc (SLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of SELLAS Life Sciences Group, Inc (SLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 198%
Institutional Ownership: 1424%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-12John Thomas BurnsVP, Finance & Corp ControllerBuy15,000.0015,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm
2020-03-12BARBARA A WOODEVP, Gen. Counsel, Corp. Sec.Buy35,000.0035,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm
2018-12-31Angelos M. StergiouPresident and CEOSell23,277.001.2529,189.36426,858.00https://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm
2020-03-12Angelos M. StergiouPresident and CEOBuy95,000.0095,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm